Nexagon

DRUG2 trials

Sponsors

Glaukos Corp., University of California, San Francisco

Conditions

Persistent Corneal Epithelial Defects

Phase 2

Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects

TerminatedNCT01165450

University of California, San FranciscoPersistent Corneal Epithelial Defects

Start: 2011-11-30End: 2014-02-28Updated: 2015-05-07

A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON ® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)

RecruitingCTIS2023-507030-24-00

Glaukos Corp.Persistent Corneal Epithelial Defects

Start: 2025-04-30Target: 60Updated: 2026-01-26